Literature DB >> 31489528

The ERK signaling pathway is involved in cardiotrophin-1-induced neural differentiation of human umbilical cord blood mesenchymal stem cells in vitro.

Changhui Lang1, Xiaomei Shu2, Longying Peng1, Xiaohua Yu1.   

Abstract

Central nervous system diseases remain the most challenging pathologies, with limited or even no therapeutic possibilities and a poor prognosis. This study aimed to investigate the differentiation properties of human umbilical cord blood mesenchymal stem cells (hUCB-MSCs) transfected with recombinant adenovirus expressing enhanced green fluorescence protein cardiotrophin-1 (Adv-EGFP-CT-1) and the possible mechanisms involved. Cells were isolated, and MSC immunophenotypes were confirmed. The resulting differentiated cells treated with Adv-EGFP-CT-1 and cultured in neural induction medium (NIM) expressed higher levels of Nestin, neuronal nuclei (NeuN) and glial fibrillary acidic protein (GFAP) markers than cells in other treatments. Expression of glycoprotein 130/leukemia inhibitory factor receptor β (gp130/LiFRβ), Raf-1, phosphorylated Raf-1 (p-Raf-1), extracellular signal-regulated kinase 1/2 (ERK1/2) and phospho-ERK1/2 (p-ERK1/2) increased gradually within 72 h after transfection with Adv-EGFP-CT-1 and NIM culture. Additionally, inhibition of extracellular signal-regulated kinase kinase (MEK) abrogated expression of p-ERK1/2, Nestin, GFAP and NeuN. Thus, the ERK1/2 pathway may contribute to CT1-stimulated neural differentiation of hUCB-MSCs.

Entities:  

Keywords:  Cardiotrophin-1; ERK/MAPK signaling pathway; Neuron-like cells; Umbilical cord blood mesenchymal stem cells

Year:  2019        PMID: 31489528      PMCID: PMC6787130          DOI: 10.1007/s10616-019-00339-w

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  29 in total

Review 1.  The role of mesenchymal stromal cells in spinal cord injury, regenerative medicine and possible clinical applications.

Authors:  Serhiy Forostyak; Pavla Jendelova; Eva Sykova
Journal:  Biochimie       Date:  2013-08-27       Impact factor: 4.079

2.  From hypertension to hypertrophy to heart failure: the role of cardiotrophin-1.

Authors:  Giuseppe Schillaci; Giacomo Pucci; Stefano Perlini
Journal:  J Hypertens       Date:  2013-03       Impact factor: 4.844

Review 3.  Cardiotrophin-1: A multifaceted cytokine.

Authors:  Miguel López-Yoldi; María J Moreno-Aliaga; Matilde Bustos
Journal:  Cytokine Growth Factor Rev       Date:  2015-07-04       Impact factor: 7.638

4.  Cardiotrophin-1 stimulates the neural differentiation of human umbilical cord blood-derived mesenchymal stem cells and survival of differentiated cells through PI3K/Akt-dependent signaling pathways.

Authors:  Longying Peng; Xiaomei Shu; Changhui Lang; Xiaohua Yu
Journal:  Cytotechnology       Date:  2017-06-10       Impact factor: 2.058

5.  Cardiotrophin-1 (CT-1) improves high fat diet-induced cognitive deficits in mice.

Authors:  Dongmei Wang; Ling Liu; Junqiang Yan; Wenlan Wu; Xiaoying Zhu; Yong Wang
Journal:  Neurochem Res       Date:  2015-02-12       Impact factor: 3.996

Review 6.  Progress of mesenchymal stem cell therapy for neural and retinal diseases.

Authors:  Tsz Kin Ng; Veronica R Fortino; Daniel Pelaez; Herman S Cheung
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

Review 7.  Effects and mechanism of organ protection by cardiotrophin-1.

Authors:  Ma B García-Cenador; J M Lopez-Novoa; J Díez; F J García-Criado
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

8.  Low immunogenicity of allogeneic human umbilical cord blood-derived mesenchymal stem cells in vitro and in vivo.

Authors:  Miyoung Lee; Sang Young Jeong; Jueun Ha; Miyeon Kim; Hye Jin Jin; Soon-Jae Kwon; Jong Wook Chang; Soo Jin Choi; Wonil Oh; Yoon Sun Yang; Jae-Sung Kim; Hong Bae Jeon
Journal:  Biochem Biophys Res Commun       Date:  2014-03-20       Impact factor: 3.575

9.  Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.

Authors:  Peter Connick; Madhan Kolappan; Charles Crawley; Daniel J Webber; Rickie Patani; Andrew W Michell; Ming-Qing Du; Shi-Lu Luan; Daniel R Altmann; Alan J Thompson; Alastair Compston; Michael A Scott; David H Miller; Siddharthan Chandran
Journal:  Lancet Neurol       Date:  2012-01-10       Impact factor: 44.182

10.  Human umbilical cord blood-derived mesenchymal stem cell therapy promotes functional recovery of contused rat spinal cord through enhancement of endogenous cell proliferation and oligogenesis.

Authors:  Sang In Park; Jung Yeon Lim; Chang Hyun Jeong; Seong Muk Kim; Jin Ae Jun; Sin-Soo Jeun; Won Il Oh
Journal:  J Biomed Biotechnol       Date:  2012-02-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.